Market growth is driven by the rising prevalence of cancer, increasing cancer research, rising investments in regenerative medicine research, rising demand for monoclonal antibodies, and rapid growth in the biotechnology and biopharmaceutical industries.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960

Primary cells are considered to be more biologically representative in comparison to cell lines owing to their very identical characteristics to the original donor tissue. Owing to this, it is becoming increasingly evident that primary cells in 3D cell cultures are capable of producing more biologically representative models of in vivo multicellular environments as compared to cell lines.

Industry Overview

Primary Cells Market size is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7%. Growth in this market is largely driven by the rising prevalence of cancer, increasing focus on the development of novel cancer therapies, and rising adoption of primary cells over cell lines. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the primary cells market.

Market Segmentation

 Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region - Global Forecast to 2025. The primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share in the primary cells market.

The major players operating in this market are  Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).

Thermo Fisher Scientific accounted for the largest share of the primary cells market in 2019. The company maintains its leading position in the primary cells market due to its well-established product portfolio. The company adopted partnerships and expansions as key strategies to strengthen its position as well as expand its product portfolio.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960

 This study involved four major activities in estimating the current size of the primary cells market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.